Tenaya Reports Early Data From First Cohort Of Patients In MyPEAK-1 Trial Of TN-201

(RTTNews) - Tenaya Therapeutics (TNYA) reported early data from the first cohort of patients in the MyPEAK-1 clinical trial of TN-201 gene therapy. TN-201 is being developed for the potential treatment of MYBPC3-associated hypertrophic cardiomyopathy, a condition caused by insufficient levels of myosin-binding protein C. The company said, taken together, the TN-201 data reported are in line with its overall expectations at the early juncture in the study.

The company said preliminary data from three patients in the first dose cohort of 3E13 vg/kg showed that TN-201 was generally well tolerated. Tenaya will continue to follow these first three patients with additional data readouts from Cohort 1 and the higher dose Cohort 2 anticipated in 2025.

Shares of Tenaya Therapeutics are down 26% in pre-market trade on Tuesday.